MTVA
MTVA
NASDAQ · Biotechnology

Metavia Inc

$1.40
-0.04 (-2.78%)
Analyst Consensus
Strong Buy
8
Analysts
Moderate
Coverage
Buy 7 88%
Hold 1 13%
Sell 0 0%
Price Target
Analyst Price Target +467.9% upside
Low Target $5.82
Average Target $7.95
High Target $9.13
Current Price $1.40
Current
$1.40
Target
$7.95
$5.82 $7.95 avg $9.13
Scenario Analysis
Bear Case
$5.82
315.7%
Low target
Base Case
$7.95
+467.9%
Avg target
Bull Case
$9.13
+552.1%
High target
Risk/Reward
1.7x
Balanced
Price in Context
52-Week High
$14.85
-90.6% from high
52-Week Low
$0.97
+44.9% from low
Target vs 52W High
$7.95
-46.5% vs high
Next Earnings Report
Nov 16, 2026
2d
until earnings
EPS Est: $-0.75
Earnings in 2 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 38 82% $257.58 -12.5%
AMGN
Amgen Inc
Hold 42 43% $190.87 -59.0%
GILD
Gilead Sciences Inc
Strong Buy 36 83% $362.68 +115.4%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 82% $438.34 -18.5%
MRNA
Moderna Inc
Hold 31 32% $149.45 -35.4%
REGN
Regeneron Pharmaceuticals
Buy 36 72% $76.80 -91.9%
NTRA
Natera Inc
Strong Buy 31 90% $142.91 -55.7%
RVMD
Revolution Medicines Inc
Strong Buy 31 94% $114.11 -35.3%